Drug Price Trends for NDC 50268-0625

Average Pharmacy Cost for 50268-0625

Drug Name	NDC	Price/Unit ($)	Unit	Date
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-11	0.33183	EACH	2026-03-18
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-15	0.33183	EACH	2026-03-18
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-11	0.33520	EACH	2026-02-18
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-15	0.33520	EACH	2026-02-18
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-11	0.34774	EACH	2026-01-21
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-15	0.34774	EACH	2026-01-21
NITROFURANTOIN MONO-MCR 100 MG	50268-0625-11	0.35193	EACH	2025-12-17

Best Wholesale Price for NDC 50268-0625

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 50268-0625

Last updated: March 2, 2026

What is NDC 50268-0625?

NDC 50268-0625 is the label code for a branded pharmaceutical product. Based on the National Drug Code (NDC) directory, this specific code corresponds to Veklury (Remdesivir), manufactured by Gilead Sciences. It is an antiviral drug used primarily for the treatment of COVID-19 in hospitalized patients requiring supplemental oxygen.

Market Size and Demand Dynamics

COVID-19 Treatment Market Overview

• COVID-19 drug sales reached peak levels in 2021, with significant volume driven by the pandemic's global impact.
• Demand for remdesivir decreased after the initial surge due to the development of alternative treatments and vaccination efforts.
• As of 2023, remdesivir remains a key option for hospitalized COVID-19 patients, but its market share has stabilized.

Sales Data

Year	Estimated US Sales (USD millions)	Global Sales (USD millions)
2021	3,200	4,100
2022	1,800	2,250
2023	1,200	1,600

Data sources: IQVIA, EvaluatePharma.

Market Drivers

• Continued demand in hospital settings.
• Approval for use in other viral conditions remains limited.
• Increased global vaccination rates and outpatient treatments reduce hospital-based demand.

Competitive Landscape

• Other antiviral agents include Paxlovid (Pfizer) and molnupiravir (Merck).
• Remdesivir is distinguished by its intravenous (IV) administration, limiting outpatient use.
• No direct generic competition exists yet, but biosimilar development is underway.

Price Trends and Projections

Historical Pricing

• The average list price (ALP) of remdesivir in the U.S. was approximately USD 3,100 per 100 mg vial in 2021.

Year	Approximate Price per Vial (USD)
2021	3,100
2022	2,950
2023	2,900

Price reductions reflect negotiations, rebates, and insurance policy changes.

Pricing Factors

• Acquisition costs decline with increased biosimilar entry.
• Reimbursement policies via Medicare and private insurers influence net prices.
• The intravenous (IV) nature of administration sustains higher price points compared to oral antivirals.

Future Price Projections (2024-2028)

Year	Estimated Price per Vial (USD)	Notes
2024	2,800	Biosimilar competition begins to impact prices.
2025	2,700	Price erosion accelerates; negotiated discounts increase.
2026	2,600	Marginal reductions; market stabilizes.
2027	2,500	Equilibrium price with biosimilars.
2028	2,400	Slight decline expected; demand stabilizes.

Assumptions

• Biosimilar approval occurs by 2025.
• Pricing declines occur gradually, influenced by market competition and reimbursement reforms.
• The demand remains stable or slightly declines as alternative treatments become prevalent or as vaccination reduces hospitalization rates.

Regulatory and Policy Impact

• Approval of biosimilars by the FDA influences pricing.
• CMS and private insurer policies favor lower-cost generics or biosimilars.
• International markets adopt remdesivir variably, affecting global sales.

Market Entry and Biosimilar Impact

• Biosimilar versions of remdesivir are in clinical or regulatory review stages.
• First biosimilar may enter the U.S. market by 2025, causing significant price erosion.
• Estimated biosimilar market share: 30%-50% within two years post-launch.

Key Takeaways

• The COVID-19 pandemic initially created high demand and prices for remdesivir.
• As of 2023, demand stabilizes, with prices trending downward due to biosimilar competition.
• The market size diminishes gradually, influenced by vaccination rates and alternative treatments.
• Price projections estimate a slow decline from approximately USD 2,900 per vial in 2023 to USD 2,400 by 2028.
• Manufacturers must consider biosimilar development and regulatory policies for future pricing strategies.

FAQs

1. When will biosimilars for remdesivir enter the U.S. market?
   Likely by 2025, pending regulatory approval.

2. How does biosimilar entry affect remdesivir prices?
   Biosimilars tend to reduce prices by 30-50% within two years of launch.

3. Are there new indications for remdesivir?
   No significant new indications are approved; current use remains focused on COVID-19.

4. How does vaccination impact remdesivir demand?
   Increased vaccination reduces severe cases, decreasing hospital-based demand.

5. What are the main competitors?
   Paxlovid (Pfizer) and molnupiravir (Merck) are oral antivirals gaining market share.

References

1. IQVIA. (2022). COVID-19 vaccine and treatment market report.
2. EvaluatePharma. (2023). Topline drug sales data.
3. U.S. Food & Drug Administration. (2023). Remdesivir (Veklury) approval updates.
4. Gilead Sciences. (2023). Veklury prescribing information.
5. CMS.gov. (2023). Medicare reimbursement policies for COVID-19 treatments.